Novartis AG ADR (NVS)vsPacific Biosciences of California (PACB)
NVS
Novartis AG ADR
$148.38
-0.99%
HEALTHCARE · Cap: $273.77B
PACB
Pacific Biosciences of California
$1.63
+3.16%
HEALTHCARE · Cap: $425.52M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 35255% more annual revenue ($56.58B vs $160.03M). NVS leads profitability with a 23.9% profit margin vs -80.3%. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
PACB
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Intrinsic value data unavailable for PACB.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
No standout strengths identified
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
0.1% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 163.0x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : PACB
PACB has a balanced fundamental profile.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : PACB
The primary concerns for PACB are Revenue Growth, EPS Growth, Market Cap. Debt-to-equity of 297.29 is elevated, increasing financial risk.
Key Dynamics to Monitor
NVS profiles as a declining stock while PACB is a turnaround play — different risk/reward profiles.
PACB carries more volatility with a beta of 2.32 — expect wider price swings.
PACB is growing revenue faster at 0.1% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 24/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Pacific Biosciences of California
HEALTHCARE · MEDICAL DEVICES · USA
Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to solve genetically complex problems. The company is headquartered in Menlo Park, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?